Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Undertreatment of Hypercholesterolaemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01027624

NIS-CZA-DUM-2009/1

Details and patient eligibility

About

This is a multi-centre survey of patients who are currently on lipid lowering pharmacological treatment in South Africa.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must be 18 years of age or older of either gender or race.
• Subject must provide informed consent and comply with the survey procedures.
• Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion criteria

• Subjects who are unwilling or unable to provide informed consent.

Trial design

3,000 participants in 1 patient group

Hyperchlesterolaemia

Description:

Participants undertreated with hypercholesterolaemia